Answers are grounded in this paper and cite their sources.
Background Ellagic acid (EA) and its gut microbiota-derived metabolites, particularly urolithin A (UA), have attracted attention because of their potential involvement in the regulation of bone remodeling. However, most available evidence comes from in vitro and animal studies, and the clinical relevance of these findings to the prevention and treatment of osteoporosis remains unclear. This review summarizes the evidence from three perspectives: gut microbial transformation, compound-specific bone effects, and human exposure and clinical evidence. Main body The gut microbiota can convert ellagitannins and EA into a variety of structurally distinct urolithins, but the production profiles differ markedly among individuals. The urolithin metabotype refers to an individual’s overall pattern of urolithin production, and to date it still cannot be used to predict skeletal responses. In preclinical models, including in vitro and animal studies, EA and some urolithins can influence processes related to bone remodeling, such as RANKL-dependent osteoclastogenesis, osteogenic differentiation, and inflammatory and oxidative stress responses. As for the mechanisms involving Wnt signaling, the NF-κB/MAPK pathway, and antioxidant responses, the evidence likewise comes from preclinical studies; the effects vary with the compound and the experimental model, making it difficult to extrapolate directly to other urolithins or to the human skeleton. Another notable issue is that circulating urolithins exist predominantly as conjugated metabolites, whereas many in vitro studies have used the free aglycone. Whether these compounds can accumulate in human bone tissue to levels sufficient to produce biological effects remains undetermined. Existing human studies have mostly focused on pharmacokinetics, short-term safety and tolerability, and some non-skeletal endpoints, and the limited bone-related evidence is insufficient to demonstrate that EA or urolithins prevent osteoporosis or fractures. Conclusions The EA–gut microbiota–urolithin metabolic axis provides clues for understanding the link between microbial metabolism and skeletal health; however, whether it exerts bona fide skeletal effects in humans remains unconfirmed. Tailoring supplementation regimens according to urolithin metabotype, modulating the gut microbiota, or implementing individualized dosing are promising but still unvalidated research directions. Future studies should incorporate actual human exposure characteristics, take into account the etiology of secondary bone loss and various confounding factors, and conduct randomized controlled trials with skeletal outcomes as primary endpoints in addition to standard anti-osteoporosis therapy, so as to clarify the true clinical value of this axis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: